

New Projects

Hudson Institute of Medical Research

Senior postdoctoral fellow, Next-Generation Precision Medicine Program


The Australian Lions Childhood Cancer Research Foundation (ALCCRF) is thrilled to announce the establishment of a prestigious national fellowship awarded to Dr. Paul Daniel at [Hudson Institute of Medical Research](#).

A cancer biologist with over a decade of experience, Dr. Daniel studies adult and paediatric brain tumours. He is currently driving cutting-edge translational research to identify better treatments for low-survival childhood brain cancers. These treatments include high-grade gliomas (Diffuse Midline Glioma, Diffuse Hemispheric Glioma), embryonal tumours (Atypical Teratoid Rhabdoid Tumours, Medulloblastoma), and other understudied rare disease types (Choroid Plexus Tumour, Primitive Neuroectodermal Tumours). The ALCCRF Fellowship is a significant step towards reinforcing Australia's research efforts in combating childhood cancers and ensuring continued advancements in medical treatments for young patients.

Dr. Daniel has made remarkable contributions to the field, particularly through his leadership in the Childhood Cancer Model Atlas (CCMA, available at: www.vicpcc.org.au/dashboard). The CCMA, the

world's largest collection of high-risk paediatric cancer cell lines, serves as a global resource for researchers aiming to find new treatments for childhood cancers. Dr. Daniel's work in developing and managing this atlas has garnered International recognition and support.

The ALCCRF Fellowship will leverage the extensive resources and global collaborations facilitated by the CCMA to produce preclinical data, guiding clinical trials and directly impact patient outcomes. Dr. Daniel's work will focus on developing combination therapies, which have shown promise in enhancing anti-tumour effects, targeting treatment failures and reducing adverse side effects. By integrating advanced AI-driven analysis and high-throughput drug screening, Dr. Daniel aims to identify and prioritize effective combination



Dr Paul Daniel

therapies for paediatric cancers. His collaborative efforts with the CONNECT2109 international clinical trial further highlight the potential for immediate patient impact.